Evidence map›Paper›PMID 31949999›Full record

ArticleDiabetology international2020

Association between changes in the mRNA expression of platelet-activating factor receptor in peripheral blood mononuclear cells and progression of diabetic nephropathy.

Sahar Ghavidel Darestani, Mihoko Kurano, Atsushi Shinnakasu, Kiyoaki Yamamoto, Yukari Dochi, Kayo Uemura, Yuko Ikeda, Aiko Arimura, Hiroshi Arimura, Akira Kikuchi and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Sahar Ghavidel DarestaniDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Mihoko KuranoDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.ORCID 0000-0003-2889-4504
Atsushi ShinnakasuDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Kiyoaki YamamotoDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Yukari DochiDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Kayo UemuraDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Yuko IkedaDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Aiko ArimuraDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Hiroshi ArimuraDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Akira KikuchiDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Hiroshi HashiguchiDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Takahisa DeguchiDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Yoshihiko NishioDepartment of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 8-35-1, Sakuragaoka, Kagoshima, 890-8520 Japan.
Kagoshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSeveral studies have recently pointed out the role of many inflammatory mediators in the progression of diabetes complications. We had previously demonstrated that mRNA expression of platelet-activating factor receptor (PAFR) in peripheral blood mononuclear cells (PBMCs) was associated with urinary albumin to creatinine ratio (ACR) and forearm flow-mediated dilatation in patients with type 2 diabetes. In an attempt to elucidate this association, patients were followed up for 1 year. MATERIALS AND

methodsWe recruited 95 patients from the hospital outpatient clinic, among whom 86 were followed up for 1 year (normoalbuminuria: 40 patients, microalbuminuria: 25 patients, macroalbuminuria: 21 patients). We then measured their baseline and 12 month characteristics and collected blood samples to extract PBMCs and measure gene expressions.

resultsDespite higher mRNA expression of PAFR in PBMCs among patients with macroalbuminuria, the rise in its value was not associated with biomarkers of nephropathy, while baseline values were not associated with progression of nephropathy. Moreover, changes in mRNA expression of PAFR were correlated with changes in ACR in all patients (

conclusionOur findings indicate that even though no causal relationship exists between diabetic nephropathy and elevated expression of PAFR in PBMCs, their close association signifies the presence of another common mechanism that could induce both events. Given these findings, the PAF/PAFR interaction could clarify corresponding mechanisms involved in diabetic complications.

Indexed as

Diabetic nephropathyFollow-up studyInflammationMacrovascular complication

Identifiers

PMID31949999
PMCPMC6942077
OpenAlexW2939737938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.